Source:http://linkedlifedata.com/resource/pubmed/id/10975007
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-9-26
|
| pubmed:abstractText |
There is little information about long-term follow-up in patients with smear-negative pulmonary tuberculosis (PTB) or extrapulmonary tuberculosis (EPTB) who have been treated under routine programme conditions in sub-Saharan Africa. A prospective study was carried out to determine outcome 32 months from start of treatment in an unselected cohort of 827 adults TB inpatients registered at Zomba Hospital, Malawi, in 1 July-31 December 1995. By 32 months, 351 (42%) patients had died. Death rates were 30% (95% confidence interval [95% CI] 25-35%) in 386 patients with smear-positive PTB, 60% (95% CI 53-67%) in 211 patients with smear-negative PTB and 47% (95% CI 40-54%) in 230 patients with EPTB. Of the 793 patients with concordant HIV test results 612 (77%) were HIV seropositive: 47% HIV-positive patients were dead by 32 months compared with 27% HIV-negative patients (adjusted hazard ratio [HR] 2.3; 95% CI 1.7-3.1, P < 0.001). Smear-negative PTB patients had the highest death rates during the 32-month follow-up (HR 2.7; 95% CI 2.1-3.5, P < 0.001 compared to smear-positive patients), followed by EPTB patients (HR 1.9; 95% CI 1.5-2.5, P < 0.001 compared to smear-positive patients). When analysis was restricted to after the treatment period had finished (i.e., months 12-32), the differences in mortality were maintained for HIV-serostatus and for types of TB. Low-cost, easy to implement strategies for reducing mortality in HIV-positive TB patients in sub-Saharan Africa (such as the use of trimethoprim-sulphamethoxazole prophylaxis) need to be tested urgently in programme settings.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0035-9203
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
305-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10975007-Adolescent,
pubmed-meshheading:10975007-Adult,
pubmed-meshheading:10975007-Aged,
pubmed-meshheading:10975007-Antitubercular Agents,
pubmed-meshheading:10975007-Child,
pubmed-meshheading:10975007-Child, Preschool,
pubmed-meshheading:10975007-Cohort Studies,
pubmed-meshheading:10975007-Female,
pubmed-meshheading:10975007-Follow-Up Studies,
pubmed-meshheading:10975007-HIV Seropositivity,
pubmed-meshheading:10975007-HIV Seroprevalence,
pubmed-meshheading:10975007-Humans,
pubmed-meshheading:10975007-Infant,
pubmed-meshheading:10975007-Infant, Newborn,
pubmed-meshheading:10975007-Malawi,
pubmed-meshheading:10975007-Male,
pubmed-meshheading:10975007-Middle Aged,
pubmed-meshheading:10975007-Prospective Studies,
pubmed-meshheading:10975007-Risk Factors,
pubmed-meshheading:10975007-Survival Analysis,
pubmed-meshheading:10975007-Tuberculosis,
pubmed-meshheading:10975007-Tuberculosis, Pulmonary
|
| pubmed:articleTitle |
High mortality rates in tuberculosis patients in Zomba Hospital, Malawi, during 32 months of follow-up.
|
| pubmed:affiliation |
College of Medicine, Chichiri, Blantyre, Malawi.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|